CXCR4 and Miyoshi myopathy: Other radiopharmaceuticals targeting alternative MM biomarkers have also shown promising results, such as radio-labeled choline, 68Ga-Pentixafor targeting C–X–C chemokine receptor type 4 (CXCR4), and immuno-PET using radiolabeled monoclonal antibodies (mAbs) as a companion of antibody-based therapies [12,13,14,15,16].